Zealand Pharma A/S, of Copenhagen, Denmark, and Brisbane, Australia-based Uniquest, the commercialization arm of The University of Queensland, have agreed to work together to identify new peptide therapies inspired by venoms as potential new treatments for gastrointestinal diseases.